confirmed that TGF-β suppresses Th2-cell-mediated cancer immunity, which promotes vessel remodeling, and that depletion of TGFBR2 in CD4+ T cells can suppress cancer progression via tissue healing and remodeling of the blood vasculature (157); thus, this group designed a strategy for targeted TGF-β signaling blockade in Th2 cells, which significantly inhibited tumor growth in mice (158). The gene discussed is TGFB1; the disease is neoplasm.